CONCLUSION
Successful Haplo-HCT utilizing an Aba- based regimen can result in
reliable engraftment and acceptable GVHD. Similar to other studies, this
supports the concept of Aba-induced immune tolerance with minimal
treatment-related morbidity. Our small sample size limits
generalizability and a prospective study incorporating abatacept as
upfront GVHD prophylaxis to validate these results in the haplo-HCT
setting is being developed at our program. Alternatives to the PTCy
regimen may be especially needed to improve outcomes for patients
requiring high risk transplants, such as those undergoing a second HCT
or have had significant previous toxicity.
Acknowledgment: None
Declaration of Interests: The authors declare no potential
interests.